News Events
Pareto Healthcare Conference, Stockholm. Carl-Johan Dalsgaard will present at this Scandinavian investor event that brings together leading healthcare providers, biotech innovators, and investors for financial presentations and panels.
DNB Carnegie “Small & Mid Cap Seminar”, Stockholm. CEO Carl-Johan Dalsgaard presents at the event.
Young Star Masters Grevagården, Skövde. Part of the sales team is representing Intervacc at this prestigious show jumping competition for young horses, attended by a large number of breeders, horse owners, and riders.
Redeye “Investor Update: Intervacc – Strangvac progress”. Carl-Johan Dalsgaard will present at the event, which will be streamed digitally between 11:00 AM and 12:30 PM (Swedish time).
Havemeyer Meeting, Kansas, USA. Workshops on equine research. Andrew Waller and Romain Pailott speak at the Havemeyer Foundation Workshop “Addressing Strangles and Other Streptococcal Diseases.” Supported by Boehringer Ingelheim Animal Health, Equine Diagnostic Solutions, Intervacc, and Merck Animal Health.
THE AGENDA
Upcoming activities
Spreading knowledge about quark, infection control and preventive animal health is an important part of Intervacc’s work. By participating in fairs, conferences and lectures, we want to contribute to increased knowledge and better animal health.
Being presented are planned activities where Intervacc participates in fairs, conferences, lectures among others.
Pareto Healthcare Conference, Stockholm. Carl-Johan Dalsgaard will present at this Scandinavian investor event that brings together leading healthcare providers, biotech innovators, and investors for financial presentations and panels.
DNB Carnegie “Small & Mid Cap Seminar”, Stockholm. CEO Carl-Johan Dalsgaard presents at the event.
Young Star Masters Grevagården, Skövde. Part of the sales team is representing Intervacc at this prestigious show jumping competition for young horses, attended by a large number of breeders, horse owners, and riders.
Redeye “Investor Update: Intervacc – Strangvac progress”. Carl-Johan Dalsgaard will present at the event, which will be streamed digitally between 11:00 AM and 12:30 PM (Swedish time).
Havemeyer Meeting, Kansas, USA. Workshops on equine research. Andrew Waller and Romain Pailott speak at the Havemeyer Foundation Workshop “Addressing Strangles and Other Streptococcal Diseases.” Supported by Boehringer Ingelheim Animal Health, Equine Diagnostic Solutions, Intervacc, and Merck Animal Health.
THE AGENDA
Upcoming activities
Raising awareness of strangles, infection control and preventive animal health is an important part of Intervacc’s work. By participating in trade fairs, meetings, training courses, conferences and lectures, we aim to contribute to greater knowledge and improved animal health.
Here we present major scheduled activities in which Intervacc participates.
With the news briefs, we want to offer an insight into the business between the regulatory news and the quarterly reports – which reflect the people, research, collaborations and activities behind the development of new vaccines and sales.
NEWS BRIEFS
Equine Specialist Program Step-1 Held by Intervacc on 17/10
Intervacc is hosting a full-day course in October at Mälaren Equine Clinic in Sigtuna. The course is approved for the “Equine Specialist Program” – a three-year full-time continuing education program for licensed veterinarians leading to specialist competence in equine diseases. The program is organized by the Swedish Veterinary Association on behalf of the Swedish Board of Agriculture.
The course theme is guttural pouch infections & guttural pouch endoscopy with a combination of theory and practice. The full program can be found here »
Strangvac® has now arrived in New Zealand
Thanks to excellent cooperation between Intervacc, Dechra, and the relevant authorities, 1,200 doses of Strangvac®, originally intended for the British market, have now arrived in Auckland to help protect horses in the Waikato region, which has unfortunately been affected by several outbreaks of strangles.
We are proud to have been able to get the delivery on-site so quickly and hope that it will contribute to the efforts to limit the outbreaks and protect the horses in the area.
Breakfast networking and lecture
Westcoast Equestrian Week (WEW) is a major summer festival and show jumping competition held at Åby Arena (Åbytravet) in Gothenburg.
Today, Intervacc took part in WEW with “Together Against Strangles” and a public breakfast lecture, “Make biosecurity routine—for the horse’s best interests”. The speakers were Emma Hartman and Anna Martinsson.
Meeting with CVB in Iowa, USA
Intervacc’s Chief Scientific Officer, Andrew Waller, and Head of Immunology, Romain Paillot, met with the Center for Veterinary Biologics (CVB) today. CVB is part of the United States Department of Agriculture (USDA), which regulates and controls biological products for animals, such as vaccines and diagnostic tools. Today’s meeting was an important and significant step in the regulatory process pathway toward market approval of Strangvac® in the United States.
Astrid and Anna-Carin Increase Their Holdings
Insider purchases between July 9-17, 2026, have been reported to FI for Chief Marketing and Sales Officer Anna-Carin Lagerlöf (120,000 shares) and Program Manager Astrid Larberg (115,484 shares).
The acquisition is linked to the company’s incentive program, LTI 2026.
The Product Portfolio Expands Further
In addition to our proprietary vaccine Strangvac®, Intervacc’s product portfolio includes a wide range of veterinary medicinal products and vaccines from the European pharmaceutical manufacturers Syva and Divasa-Farmavic in Spain, Animalcare in the United Kingdom, and Chemvet in Denmark.
Today, the range was expanded with an equine ointment from Derma Advanced.
With our news items, we aim to offer insight into our operations between regulatory news and quarterly reports, reflecting the people, the research, the collaborations and the day-to-day work behind the development of new vaccines and sales.
Equine Specialist Program Step-1 Held by Intervacc on 17/10
Intervacc is hosting a full-day course in October at Mälaren Equine Clinic in Sigtuna. The course is approved for the “Equine Specialist Program” – a three-year full-time continuing education program for licensed veterinarians leading to specialist competence in equine diseases. The program is organized by the Swedish Veterinary Association on behalf of the Swedish Board of Agriculture.
The course theme is guttural pouch infections & guttural pouch endoscopy with a combination of theory and practice. The full program can be found here »
Strangvac® has now arrived in New Zealand
Thanks to excellent cooperation between Intervacc, Dechra, and the relevant authorities, 1,200 doses of Strangvac®, originally intended for the British market, have now arrived in Auckland to help protect horses in the Waikato region, which has unfortunately been affected by several outbreaks of strangles.
We are proud to have been able to get the delivery on-site so quickly and hope that it will contribute to the efforts to limit the outbreaks and protect the horses in the area.
Breakfast networking and lecture
Westcoast Equestrian Week (WEW) is a major summer festival and show jumping competition held at Åby Arena (Åbytravet) in Gothenburg.
Today, Intervacc took part in WEW with “Together Against Strangles” and a public breakfast lecture, “Make biosecurity routine—for the horse’s best interests”. The speakers were Emma Hartman and Anna Martinsson.
Meeting with CVB in Iowa, USA
Intervacc’s Chief Scientific Officer, Andrew Waller, and Head of Immunology, Romain Paillot, met with the Center for Veterinary Biologics (CVB) today. CVB is part of the United States Department of Agriculture (USDA), which regulates and controls biological products for animals, such as vaccines and diagnostic tools. Today’s meeting was an important and significant step in the regulatory process pathway toward market approval of Strangvac® in the United States.
Astrid and Anna-Carin Increase Their Holdings
Insider purchases between July 9-17, 2026, have been reported to FI for Chief Marketing and Sales Officer Anna-Carin Lagerlöf (120,000 shares) and Program Manager Astrid Larberg (115,484 shares).
The acquisition is linked to the company’s incentive program, LTI 2026.
The Product Portfolio Expands Further
In addition to our proprietary vaccine Strangvac®, Intervacc’s product portfolio includes a wide range of veterinary medicinal products and vaccines from the European pharmaceutical manufacturers Syva and Divasa-Farmavic in Spain, Animalcare in the United Kingdom, and Chemvet in Denmark.
Today, the range was expanded with an equine ointment from Derma Advanced.
NEWS BRIEFS
Equine Specialist Program Step-1 Held by Intervacc on 17/10
Intervacc is hosting a full-day course in October at Mälaren Equine Clinic in Sigtuna. The course is approved for the “Equine Specialist Program” – a three-year full-time continuing education program for licensed veterinarians leading to specialist competence in equine diseases. The program is organized by the Swedish Veterinary Association on behalf of the Swedish Board of Agriculture.
The course theme is guttural pouch infections & guttural pouch endoscopy with a combination of theory and practice. The full program can be found here »
Strangvac® has now arrived in New Zealand
Thanks to excellent cooperation between Intervacc, Dechra, and the relevant authorities, 1,200 doses of Strangvac®, originally intended for the British market, have now arrived in Auckland to help protect horses in the Waikato region, which has unfortunately been affected by several outbreaks of strangles.
We are proud to have been able to get the delivery on-site so quickly and hope that it will contribute to the efforts to limit the outbreaks and protect the horses in the area.
Breakfast networking and lecture
Westcoast Equestrian Week (WEW) is a major summer festival and show jumping competition held at Åby Arena (Åbytravet) in Gothenburg.
Today, Intervacc took part in WEW with “Together Against Strangles” and a public breakfast lecture, “Make biosecurity routine—for the horse’s best interests”. The speakers were Emma Hartman and Anna Martinsson.
Meeting with CVB in Iowa, USA
Intervacc’s Chief Scientific Officer, Andrew Waller, and Head of Immunology, Romain Paillot, met with the Center for Veterinary Biologics (CVB) today. CVB is part of the United States Department of Agriculture (USDA), which regulates and controls biological products for animals, such as vaccines and diagnostic tools. Today’s meeting was an important and significant step in the regulatory process pathway toward market approval of Strangvac® in the United States.
Astrid and Anna-Carin Increase Their Holdings
Insider purchases between July 9-17, 2026, have been reported to FI for Chief Marketing and Sales Officer Anna-Carin Lagerlöf (120,000 shares) and Program Manager Astrid Larberg (115,484 shares).
The acquisition is linked to the company’s incentive program, LTI 2026.
The Product Portfolio Expands Further
In addition to our proprietary vaccine Strangvac®, Intervacc’s product portfolio includes a wide range of veterinary medicinal products and vaccines from the European pharmaceutical manufacturers Syva and Divasa-Farmavic in Spain, Animalcare in the United Kingdom, and Chemvet in Denmark.
Today, the range was expanded with an equine ointment from Derma Advanced.